AIM: £3.68 (-0.02) | Nasdaq: $23.57 (-0.04)
News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
1
2345678910111213
found Documents: 630
Corporate presentations, Presentations | 18 Nov 2019

Corporate presentation
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 13 Nov 2019

Deutsche Bank ADR Virtual Investor Conference (dbVIC)
Live virtual investor conference. Time: 01:30 pm GMT (09:30 pm HKT/08:30 am EST) >> Click here for the webcast  
Read More
Download Presentation (PDF)
Event | 13 Nov 2019

Jefferies University Specialist Speakers Summit
JW Marriott, Hong Kong
Event | 13 Nov 2019

BioCentury & Bayhelix China Healthcare Summit
Presentation Date: Wednesday Nov 20, 2019 Presentation Time: 1:30 pm (China Time) Location: Jing An Shangri-La, Shanghai
Read More
Event | 12 Nov 2019

Daiwa Investment Conference Hong Kong
Island Shangri-La, Hong Kong
Group, Press Releases | 11 Nov 2019

Chi-Med to Attend Upcoming Investor and Industry Conferences
London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences: Deutsche Bank Depositary Receipts Virt
Read More
Download Press Release (PDF)
Innovation Platform, RNS Announcements | 11 Nov 2019

Chi-Med Announces NDA Acceptance in China for Surufatinib in Non-Pancreatic Neuroendocrine Tumors
London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine
Read More
View Announcement (PDF)
Broker Coverage | 22 Oct 2019

Bank of America Merrill Lynch
Dr. Alec W. Stranahan +1 646 743 2109 alec.stranahan@bofa.com
Read More
Event | 21 Oct 2019

Piper Jaffray 31st Annual Healthcare Conference
Lotte New York Palace, New York >>  Send us your inquiry
Read More
Event | 21 Oct 2019

Morgan Stanley 18th Annual Asia Pacific Summit
Mandarin Oriental, Singapore
Event | 21 Oct 2019

Goldman Sachs Asia Pacific Healthcare Forum 2019
Presentation Date: Monday Nov 25, 2019 Presentation Time: 11:30 am (HKT) Location: Conrad Hotel, Hong Kong  
Read More
Event | 21 Oct 2019

Credit Suisse China Investment Conference 2019
Futian Shangri-La, Shenzhen
Event | 21 Oct 2019

Citi China Investor Conference 2019
Grand Hyatt Hotel, Macau
Event | 21 Oct 2019

Jefferies 2019 London Healthcare Conference
Waldorf Hilton, London >>  Send us your inquiry
Read More
Innovation Platform, Press Releases, RNS Announcements | 17 Oct 2019

Chi-Med highlights publication of Phase II data showing promising efficacy for Savolitinib in MET-amplified gastric cancers
London: Thursday, October 17, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial in Ca
Read More
Download Press Release (PDF)
Event | 11 Oct 2019

Morgan Stanley China Biotech Bus Tour
Morgan Stanley Office, Shanghai
Regulatory Notice, RNS Announcements | 10 Oct 2019

Grant of Share Options under Share Option Scheme
London: Thursday, October 10, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Me
Read More
View Announcement (PDF)
Innovation Platform, Press Releases, RNS Announcements | 10 Oct 2019

Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors
Suzhou, China and London, UK, Thursday, October 10, 2019 — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration ag
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 4 Oct 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
London: Friday, October 4, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refr
Read More
Download Press Release (PDF)
Regulatory Notice, RNS Announcements | 3 Oct 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Group, RNS Announcements | 30 Sep 2019

CK Hutchison prices offering of Chi-Med share capital enabling deconsolidation and confirms its intention to hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
View Announcement (PDF)
Group, RNS Announcements | 30 Sep 2019

CK Hutchison offers 1.3% of Chi-Med’s share capital aiming to deconsolidate and hold Chi-Med as a strategic investment for the long term
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
View Announcement (PDF)
Regulatory Notice, RNS Announcements | 30 Sep 2019

Total Voting Rights
London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2019, the issued share capital of Chi-Med consisted of 666,786,450 ordinary shares of US$0.10 e
Read More
View Announcement (PDF)
Corporate presentations, Event, Presentations | 30 Sep 2019

Post-ESMO Surufatinib Update
Press release released:  September 29, 2019 (Sun)  >> See press release here Presentation webcast & call:  September 30, 2019 (Mon) 2pm CEST (1pm BST/8am EDT/8pm HKT) >> Click here for the webcast replay
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 29 Sep 2019

ESMO 2019: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic NETs
Title:   Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic Neuroendocrine Tumors: Results from the Randomized Phase III Study (SANET-ep) Presenting Author: Jianming Xu, Head of th
Read More
Download Presentation (PDF)
Innovation Platform, Press Releases, RNS Announcements | 29 Sep 2019

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 25 Sep 2019

Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond
Read More
Download Press Release (PDF)
Presentations, Scientific Publications | 21 Sep 2019

CSCO 2019: Association Between Hand-Foot Skin Reaction (HFSR) and Survival Benefit of Fruquintinib in FRESCO Trial
Presentation Title : Association Between Hand-Foot Skin Reaction and Survival Benefit of Fruquintinib in FRESCO Trial Presenting Author: Yuxian Bai, Harbin Medical University Cancer Hospital Other Authors: Jin Li, Shukui Qin, Yanho
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 19 Sep 2019

CSCO 2019 : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis
Presentation Title : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis Presenting Author: Shukui Qin, Nanjing Chinese Medicine University Affiliated Bay
Read More
Download Presentation (PDF)
Innovation Platform, Press Releases, RNS Announcements | 18 Sep 2019

Chi-Med Highlights Oral Presentations at 2019 CSCO Annual Meeting
London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C
Read More
Download Press Release (PDF)
Event | 13 Sep 2019

Morgan Stanley China Healthcare Corporate Day
Morgan Stanley Office, Hong Kong
Event | 13 Sep 2019

Macquarie China Healthcare Corporate Day
Macquarie Office, Hong Kong
Presentations, Scientific Publications | 9 Sep 2019

WCLC 2019: Phase III Fruquintinib v.s. Placebo in Advanced Non-Small Cell Lung Cancer (FALUCA)
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)   Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget
Read More
Download Presentation (PDF)
Corporate presentations, Event, Presentations | 9 Sep 2019

CLSA Investors' Forum 2019
Grand Hyatt, Hong Kong
Download Presentation (PDF)
Event | 5 Sep 2019

Morgan Stanley 17th Annual Global Healthcare Conference
Location: New York, NY, United States Time: 09:55 AM EDT >> Click here for the webcast  
Read More
Group, Press Releases, RNS Announcements | 3 Sep 2019

Chi-Med to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C
Read More
Download Press Release (PDF)
Innovation Platform, Press Releases, RNS Announcements | 3 Sep 2019

Chi-Med Initiates an International Phase I/Ib Trial of HMPL-689 in Patients with Advanced Relapsed or Refractory Lymphoma
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta
Read More
Download Press Release (PDF)
Regulatory Notice, RNS Announcements | 30 Aug 2019

Total Voting Rights
London: Friday, August 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 30, 2019, the issued share capital of Chi-Med consisted of 666,777,450 ordinary shares of US$0.10 each, w
Read More
View Announcement (PDF)
Innovation Platform, Press Releases, RNS Announcements | 23 Aug 2019

Chi-Med Initiates a Phase I Trial of HMPL-523 in Patients with Immune Thrombocytopenia (ITP) in China
London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”
Read More
Download Press Release (PDF)
Regulatory Notice, RNS Announcements | 20 Aug 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Interim Reports | 14 Aug 2019

Interim Report 2019
Contents Corporate Information Contents 1 Financial Highlights 2 Operating Highlights 3 Chairman’s Statement6 6 Financial Review 7 Operations Review     Innovation Platform     Comme
Read More
View Full Report (PDF)
Regulatory Notice, RNS Announcements | 30 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Corporate presentations, Event, Presentations | 30 Jul 2019

2019 Half-Year Financial Results
Announcement released: 7am BST (2pm HKT/2am EDT)  >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9pm HKT)
Read More
Download Presentation (PDF)
Group, RNS Announcements | 30 Jul 2019

Chi-Med Reports 2019 Interim Results and Provides Updates on Key Clinical Programs
London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.  Major highlight
Read More
Download Announcement (PDF)
Regulatory Notice, RNS Announcements | 3 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
View Announcement (PDF)
Regulatory Notice, RNS Announcements | 3 Jul 2019

TR-1: Form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
View Announcement (PDF)
Group, RNS Announcements | 3 Jul 2019

Chi-Med to Announce 2019 Half-Year Financial Results
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm
Read More
View Announcement (PDF)
Regulatory Notice, RNS Announcements | 28 Jun 2019

Blocklisting Six Monthly Return
London: Friday, June 28, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limite
Read More
Download Announcement (PDF)
Group, RNS Announcements | 28 Jun 2019

Chi-Med Announces Pricing of Upsized U.S. Public Secondary Offering of American Depositary Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 28, 2019: Hutchison China MediTech Limited (“
Read More
Download Announcement (PDF)
Group, RNS Announcements | 27 Jun 2019

Chi-Med Announces Secondary Offering of American Depositary Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 27, 2019: Hutchison China MediTech Limited (“
Read More
Download Announcement (PDF)
1
2345678910111213